Biotech venture capital off to a $659m start in 2015

Just six days into 2015, the US biotechnology industry already is halfway to the $1.1bn in venture capital raised during the first three months of 2014, including a $48m Series B round for Global Blood Therapeutics (GBT), a $65m Series D for Seres Health and a $20m Series C for CytomX.